NasdaqCM - Nasdaq Real Time Price USD

Fennec Pharmaceuticals Inc. (FENC)

Compare
4.6200 +0.1000 (+2.21%)
At close: October 4 at 4:00 PM EDT
Loading Chart for FENC
DELL
  • Previous Close 4.5200
  • Open 4.5800
  • Bid 4.6000 x 100
  • Ask 4.6400 x 200
  • Day's Range 4.5500 - 4.7000
  • 52 Week Range 4.5000 - 11.9200
  • Volume 64,556
  • Avg. Volume 85,790
  • Market Cap (intraday) 126.425M
  • Beta (5Y Monthly) 0.25
  • PE Ratio (TTM) 66.00
  • EPS (TTM) 0.0700
  • Earnings Date Nov 4, 2024 - Nov 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 15.50

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

www.fennecpharma.com

29

Full Time Employees

December 31

Fiscal Year Ends

Recent News: FENC

View More

Performance Overview: FENC

Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

FENC
58.82%
S&P/TSX Composite index
15.29%

1-Year Return

FENC
34.28%
S&P/TSX Composite index
27.03%

3-Year Return

FENC
50.43%
S&P/TSX Composite index
19.91%

5-Year Return

FENC
3.82%
S&P/TSX Composite index
47.61%

Compare To: FENC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: FENC

View More

Valuation Measures

Annual
As of 10/4/2024
  • Market Cap

    126.43M

  • Enterprise Value

    115.16M

  • Trailing P/E

    66.00

  • Forward P/E

    10.35

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.69

  • Price/Book (mrq)

    57.93

  • Enterprise Value/Revenue

    2.36

  • Enterprise Value/EBITDA

    17.49

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.59%

  • Return on Assets (ttm)

    8.88%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    48.89M

  • Net Income Avi to Common (ttm)

    2.73M

  • Diluted EPS (ttm)

    0.0700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    43.05M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -4.87M

Research Analysis: FENC

View More

Company Insights: FENC

Research Reports: FENC

View More

People Also Watch